Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
6(85.7%)
Phase 4
1(14.3%)
7Total
N/A(6)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT06685146Not ApplicableCompleted

The Glucose-Independent Effects of Exogenous Glucagon on Insulin Secretion and Cognitive Function in Healthy Subjects

Role: lead

NCT06877208Not ApplicableActive Not Recruiting

The Effect of Glucagon on Cerebral Glucose Metabolism in Healthy Humans

Role: lead

NCT07350512Not ApplicableNot Yet Recruiting

Investigating the Acute Effects of Increasing Alanine Exposure in Healthy Participants

Role: lead

NCT06921824Not ApplicableCompleted

Investigating the Acute Effects of Increasing Glucagon Exposure in Healthy Participants

Role: lead

NCT06647368Not ApplicableRecruiting

Development of a Non-invasive Method for Quantifying Cerebral Glucose Metabolism for Studying the Effect of Glucagon in Humans

Role: lead

NCT03520062Not ApplicableCompleted

The Effect of Liraglutide on Pancreatic Hormones and Its Size

Role: lead

NCT03717688Phase 4Completed

The Effects of Neprilysin on Glucagon-like Peptide-1

Role: lead

All 7 trials loaded